Argenx (ARGX) announced that Karen Massey will join Argenx as COO effective March 13. Massey will succeed Keith Woods, who will remain at Argenx for a transition period to support the launch of subcutaneous efgartigimod, after which he will retire and serve as a strategic advisor on the Commercial Committee of the Argenx board. Massey joins Argenx from Genentech (RHHBY), where she most recently served as senior VP of product development and global clinical operations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARGX:
- argenx Announces Planned Transition of Chief Operating Officer
- argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
- argenx Appoints Steve Krognes to Board of Directors
- argenx to Present at Upcoming Investor Conferences
- Argenx price target raised to $475 from $465 at Piper Sandler